An Open-label Study to Evaluate the Effect of Repeated Oral Administration of 200 mg Itraconazole(ITZ) Given Once Daily Over 14 Days on the Single Oral Dose Pharmacokinetics of Vilaprisan (BAY1002670) as Well as Assessment of Absolute Bioavailability Using a Single Intravenous Microtracer Dose of [14C]Vilaprisan in Healthy Postmenopausal Women

Trial Profile

An Open-label Study to Evaluate the Effect of Repeated Oral Administration of 200 mg Itraconazole(ITZ) Given Once Daily Over 14 Days on the Single Oral Dose Pharmacokinetics of Vilaprisan (BAY1002670) as Well as Assessment of Absolute Bioavailability Using a Single Intravenous Microtracer Dose of [14C]Vilaprisan in Healthy Postmenopausal Women

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Mar 2016

At a glance

  • Drugs Vilaprisan (Primary) ; Itraconazole
  • Indications Endometriosis; Uterine leiomyoma
  • Focus Pharmacokinetics
  • Sponsors Bayer
  • Most Recent Events

    • 01 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 03 Feb 2016 Planned End Date changed from 1 Jan 2016 to 1 Feb 2016 as reported by ClinicalTrials.gov record.
    • 06 Jan 2016 Planned End Date changed from 1 Nov 2015 to 1 Jan 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top